Dana-Farber Cancer Institute

Philip J. Kranzusch, PhD, was one of three scientists awarded top honors at the 2025 Blavatnik National Awards for Young Scientists.

Proton therapy provides pediatric patients a treatment option that minimizes impact on long-term growth and development.

Five new faculty members have joined the Roswell Park Care Network, with St. Joseph’s Health in Syracuse to begin thoracic surgery services.

Through a new agreement, nurse scientists from Dana-Farber will become Northeastern faculty members, bringing oncology nursing science into the classroom.

Dana-Farber researchers have provided the mechanistic and preclinical evidence needed to support a clinical trial of a new class of drugs called direct cyclin inhibitors in patients with a range of cancers.

Findings from the Breast Cancer Weight Loss (BWEL) clinical trial set the stage for ongoing research to determine if weight loss following breast cancer treatment can reduce the risk of cancer recurrence and extend survival.

Alice T. Shaw, MD, PhD, has been named Chair of the Department of Medical Oncology at Dana-Farber Cancer Institute.

Dana-Farber Cancer Institute researchers have developed a blood test that could help transform the diagnosis and monitoring of multiple myeloma.

Fewer than 1 in 5 U.S. adults aged 45-49 screened for colorectal cancer, despite guidelines

A study led by Dana-Farber Cancer Institute researchers found that chemoimmunotherapy before surgery for stage III NSCLC can help make surgery possible. 

Dana-Farber researchers unveil insights into aggressive pediatric brain tumors, paving the way for targeted therapies and improved patient outcomes.

A Dana-Farber study shows that an anti-inflammatory diet could extend overall survival after treatment for stage III colon cancer.

Dana-Farber researchers unveil insights into aggressive pediatric brain tumors, paving the way for targeted therapies and improved patient outcomes.

Dana-Farber Cancer Institute opened the Ning Zhao & Ge Li Simulation Center, which is devoted exclusively to ambulatory oncology care.

Dana-Farber Cancer Institute highlights research being presented at the 2025 AACR Annual Meeting.

Investigators found that the cancer-controlling effects of immune checkpoint inhibitors continue even after treatment is stopped due to immune-related adverse events in patients with advanced NSCLC.

Three researchers from Dana-Farber Cancer Institute have been selected by the American Association for Cancer Research (AACR) as recipients of 2025 Scientific Achievement Awards.

K. “Vish” Viswanath, PhD, of Dana-Farber Cancer Center, has been named Fellow of the American Association for the Advancement of Science.

A study showed transcription factor networks disproportionately enrich for heritability of blood cell phenotypes.

Count Me In, a patient-partnered research initiative led by Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard, is launching a project focused on translocation renal cell carcinoma.

Kimberly Stegmaier, MD, was recently named Chair of Pediatric Oncology at Dana-Farber Cancer Institute.

Patients in a clinical trial being treated for stage III or IV clear cell renal cell carcinoma generated successful responses after a personalized cancer vaccine.

The model, called EpiBERT, was inspired by BERT, a deep learning model designed to understand and generate human-like language.

Patients with evidence of residual cancer in their blood after surgery, may benefit from adding of celecoxib to post surgery treatment.

Researchers at Dana-Farber Cancer Institute have developed a breakthrough method to detect inflammation in the body using positron emission tomography (PET) imaging.

Stem cell transplant programs at the Dana-Farber Brigham Cancer Center received outstanding reviews from the CIBMTR.

Dana-Farber Cancer Institute and Gustave Roussy have announced that the topic of the Fourth Transatlantic Exchange in Oncology Conference will be “Radiopharmaceutical Therapy Meets Oncology.”

Dana-Farber Cancer Institute will launch the Center for RAS Therapeutics to advance scientific investigation and clinical care for RAS-driven cancers.

Researchers from Dana-Farber Cancer Institute will present more than 30 research studies at the 47th annual San Antonio Breast Cancer Symposium

Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanoma.